Noninferiority Randomized Trial of AI-Augmented Mammography Reading in Breast Cancer Screening
“Our study is the first randomized controlled trial investigating the use of AI in breast cancer screening and the largest to date looking at AI use in cancer screening in general,” said study author Kristina Lång, PhD.
The MASAI trial demonstrated that AI-supported mammography readings resulted in fewer interval breast cancer diagnoses compared to standard double readings.
2
AI-supported screening improved early detection of clinically relevant breast cancers, leading to fewer aggressive cancers diagnosed between screenings.
3
The trial included 105,934 women, with the intervention group showing a lower interval cancer rate of 1.55 per 1,000 participants.
4
Sensitivity was significantly higher in the AI-supported group at 80.5%, while specificity remained unchanged at 98.5% for both groups.
5
AI support reduced radiologists' workload by 44%, allowing them to focus on other clinical tasks and potentially shorten patient waiting times.
ASCO AI in Oncology
is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in
ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.